Sustained dasatinib treatment prevents early fibrotic changes following ocular trauma
Abstract
Posterior ocular trauma and the subsequent fibrotic retinal complication termed proliferative vitreoretinopathy (PVR) are leading causes of blindness in children and young adults. A previous study suggested that changes occurring within the first month post-trauma can lead to development of PVR later. The aim of this study was to examine the effect of dasatinib, a tyrosine kinase inhibitor clinically used to treat chronic myeloid leukemia, on fibrotic changes occurring within the first month following ocular trauma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 08, 2021
- Source ID
- 10.1007/s00417-020-05037-4
Entities
People
- Betty M. Nunn
- Henry J. Kaplan
- Kevin McDonald
- Martin G. O'toole
- Rajat Chauhan
- Shigeo Tamiya
- Shunichiro Ueda
Organizations
- Research to Prevent Blindness